• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

日本医疗保健体系中的癌症表型诊断与药物疗效

Cancer Phenotype Diagnosis and Drug Efficacy within Japanese Health Care.

作者信息

Nishimura Toshihide, Kato Harubumi, Ikeda Norihiko, Kihara Makoto, Nomura Masaharu, Kato Yasufumi, Marko-Varga György

机构信息

Department of Surgery, Tokyo Medical University, 6-7-1 Nishi Shinjuku Shinjuku-ku, Tokyo 160-0023, Japan.

出版信息

Int J Proteomics. 2012;2012:921901. doi: 10.1155/2012/921901. Epub 2012 May 22.

DOI:10.1155/2012/921901
PMID:22685658
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3364583/
Abstract

An overview on targeted personalized medicine is given describing the developments in Japan of lung cancer patients. These new targeted therapies with novel personalized medicine drugs require new implementations, in order to follow and monitor drug efficacy and outcome. Examples from IRESSA (Gefitinib) and TARCEVA (Erlotinib) treatments used in medication of lung cancer patients are presented. Lung cancer is one of the most common causes of cancer mortality in the world. The importance of both the quantification of disease progression, where diagnostic-related biomarkers are being implemented, in addition to the actual measurement of disease-specific mechanisms relating to pathway signalling activation of disease-progressive protein targets is summarised. An outline is also presented, describing changes and adaptations in Japan, meeting the rising costs and challenges. Today, urgent implementation of programs to address these needs has led to a rebuilding of the entire approach of medical evaluation and clinical care.

摘要

本文概述了靶向个性化医疗，并描述了日本肺癌患者的治疗进展。这些采用新型个性化药物的新靶向疗法需要新的实施方式，以便跟踪和监测药物疗效及治疗结果。文中列举了用于肺癌患者治疗的易瑞沙（吉非替尼）和特罗凯（厄洛替尼）的用药实例。肺癌是全球癌症死亡的最常见原因之一。总结了疾病进展量化的重要性，其中正在采用与诊断相关的生物标志物，此外还实际测量了与疾病进展蛋白靶点的通路信号激活相关的疾病特异性机制。还概述了日本为应对成本上升和挑战而做出的变化与调整。如今，为满足这些需求而紧急实施的项目已促使医疗评估和临床护理的整体方法得以重塑。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b8a2/3364583/6b72db40e723/IJPRO2012-921901.006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b8a2/3364583/1d91cc1dd25d/IJPRO2012-921901.001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b8a2/3364583/5634625867e5/IJPRO2012-921901.002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b8a2/3364583/4b8a6d07b705/IJPRO2012-921901.003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b8a2/3364583/f7fb66ee91ad/IJPRO2012-921901.004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b8a2/3364583/b0392d578f67/IJPRO2012-921901.005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b8a2/3364583/6b72db40e723/IJPRO2012-921901.006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b8a2/3364583/1d91cc1dd25d/IJPRO2012-921901.001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b8a2/3364583/5634625867e5/IJPRO2012-921901.002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b8a2/3364583/4b8a6d07b705/IJPRO2012-921901.003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b8a2/3364583/f7fb66ee91ad/IJPRO2012-921901.004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b8a2/3364583/b0392d578f67/IJPRO2012-921901.005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b8a2/3364583/6b72db40e723/IJPRO2012-921901.006.jpg

相似文献

1
Cancer Phenotype Diagnosis and Drug Efficacy within Japanese Health Care.日本医疗保健体系中的癌症表型诊断与药物疗效
Int J Proteomics. 2012;2012:921901. doi: 10.1155/2012/921901. Epub 2012 May 22.
2
Erlotinib and gefitinib for treating non-small cell lung cancer that has progressed following prior chemotherapy (review of NICE technology appraisals 162 and 175): a systematic review and economic evaluation.厄洛替尼和吉非替尼用于治疗先前化疗后进展的非小细胞肺癌（英国国家卫生与临床优化研究所技术评估162和175回顾）：一项系统评价与经济学评估
Health Technol Assess. 2015 Jun;19(47):1-134. doi: 10.3310/hta19470.
3
A clinician view and experience of proteomic studies in the light of lung cancer in Japanese healthcare.从日本医疗保健角度看肺癌的蛋白质组学研究：临床医生的观点和经验
J Proteome Res. 2011 Jan 7;10(1):51-7. doi: 10.1021/pr100859b.
4
Drug localization in different lung cancer phenotypes by MALDI mass spectrometry imaging.基质辅助激光解吸电离质谱成像技术在不同肺癌表型中的药物定位研究。
J Proteomics. 2011 Jun 10;74(7):982-92. doi: 10.1016/j.jprot.2011.03.019. Epub 2011 Apr 1.
5
Erlotinib: CP 358774, NSC 718781, OSI 774, R 1415.厄洛替尼：CP 358774、NSC 718781、OSI 774、R 1415。
Drugs R D. 2003;4(4):243-8. doi: 10.2165/00126839-200304040-00006.
6
Developments for a growing Japanese patient population: facilitating new technologies for future health care.针对日益增长的日本患者群体的发展：为未来的医疗保健提供新技术支持。
J Proteomics. 2011 May 16;74(6):759-64. doi: 10.1016/j.jprot.2010.12.006. Epub 2010 Dec 22.
7
Interstitial lung disease following erlotinib (Tarceva) in a patient who previously tolerated gefitinib (Iressa).一名先前耐受吉非替尼（易瑞沙）的患者在使用厄洛替尼（特罗凯）后出现间质性肺病。
J Oncol Pharm Pract. 2005 Sep;11(3):127-30. doi: 10.1191/1078155205jp158cr.
8
The future of Cochrane Neonatal.考克兰新生儿协作网的未来。
Early Hum Dev. 2020 Nov;150:105191. doi: 10.1016/j.earlhumdev.2020.105191. Epub 2020 Sep 12.
9
Japan as the front-runner of super-aged societies: Perspectives from medicine and medical care in Japan.日本作为超老龄化社会的领跑者：来自日本医学与医疗护理的视角
Geriatr Gerontol Int. 2015 Jun;15(6):673-87. doi: 10.1111/ggi.12450. Epub 2015 Feb 5.
10
Theme: oncology--molecular mechanisms determining the efficacy of EGF receptor-specific tyrosine kinase inhibitors help to identify biomarker candidates.主题：肿瘤学——决定表皮生长因子受体特异性酪氨酸激酶抑制剂疗效的分子机制有助于鉴定生物标志物候选物。
Biomark Med. 2009 Apr;3(2):139-51. doi: 10.2217/bmm.09.9.

引用本文的文献

1
Clinical initiatives linking Japanese and Swedish healthcare resources on cancer studies utilizing Biobank Repositories.利用生物样本库在癌症研究方面将日本和瑞典医疗资源联系起来的临床举措。
Clin Transl Med. 2014 Nov 22;3(1):61. doi: 10.1186/s40169-014-0038-x. eCollection 2014 Dec.

本文引用的文献

1
Preferential expression of potential markers for cancer stem cells in large cell neuroendocrine carcinoma of the lung. An FFPE proteomic study.肺癌大细胞神经内分泌癌中癌症干细胞潜在标志物的优先表达。一项福尔马林固定石蜡包埋组织蛋白质组学研究。
J Clin Bioinforma. 2011 Sep 3;1(1):23. doi: 10.1186/2043-9113-1-23.
2
Proteomic biomarkers for acute interstitial lung disease in gefitinib-treated Japanese lung cancer patients.吉非替尼治疗的日本肺癌患者急性间质性肺病的蛋白质组学生物标志物。
PLoS One. 2011;6(7):e22062. doi: 10.1371/journal.pone.0022062. Epub 2011 Jul 20.
3
Drug localization in different lung cancer phenotypes by MALDI mass spectrometry imaging.
基质辅助激光解吸电离质谱成像技术在不同肺癌表型中的药物定位研究。
J Proteomics. 2011 Jun 10;74(7):982-92. doi: 10.1016/j.jprot.2011.03.019. Epub 2011 Apr 1.
4
On the development of plasma protein biomarkers.关于血浆蛋白质生物标志物的发展。
J Proteome Res. 2011 Jan 7;10(1):5-16. doi: 10.1021/pr1008515. Epub 2010 Dec 13.
5
A clinician view and experience of proteomic studies in the light of lung cancer in Japanese healthcare.从日本医疗保健角度看肺癌的蛋白质组学研究：临床医生的观点和经验
J Proteome Res. 2011 Jan 7;10(1):51-7. doi: 10.1021/pr100859b.
6
Integrating molecular diagnostics into anticancer drug discovery.将分子诊断学纳入抗癌药物研发。
Nat Rev Drug Discov. 2010 Jul;9(7):523-35. doi: 10.1038/nrd3135. Epub 2010 Jun 7.
7
Clinical protein science and bioanalytical mass spectrometry with an emphasis on lung cancer.
Chem Rev. 2010 May 12;110(5):3278-98. doi: 10.1021/cr100011x.
8
High-throughput generation of selected reaction-monitoring assays for proteins and proteomes.高通量生成用于蛋白质和蛋白质组的选择反应监测分析方法。
Nat Methods. 2010 Jan;7(1):43-6. doi: 10.1038/nmeth.1408. Epub 2009 Dec 6.
9
Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma.吉非替尼或卡铂-紫杉醇用于治疗肺腺癌。
N Engl J Med. 2009 Sep 3;361(10):947-57. doi: 10.1056/NEJMoa0810699. Epub 2009 Aug 19.
10
Multi-site assessment of the precision and reproducibility of multiple reaction monitoring-based measurements of proteins in plasma.基于多反应监测的血浆蛋白质测量的精密度和重现性的多中心评估。
Nat Biotechnol. 2009 Jul;27(7):633-41. doi: 10.1038/nbt.1546. Epub 2009 Jun 28.